Accordingly, interruption of the EGFR signalling pathway using small-molecule tyrosine kinase inhibitors (TKIs) is considered as a well-established therapeutic approach in cancer treatment since the approval of gefitinib by the United States Food and Drug Administration (FDA) in 20039,.10 Here, EGFR is linked to cancer.